Cyteir Therapeutics Inc is a biotechnology business based in the US. Cyteir Therapeutics shares (CYT) are listed on the NASDAQ and all prices are listed in US Dollars. Cyteir Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Cyteir Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CYT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

Cyteir Therapeutics stock price (NASDAQ: CYT)
Use our graph to track the performance of CYT stocks over time.Cyteir Therapeutics shares at a glance
Latest market close | $3.04 |
---|---|
52-week range | $1.56 - $23.10 |
50-day moving average | $2.30 |
200-day moving average | $8.82 |
Wall St. target price | $13.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.76 |
Buy Cyteir Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Cyteir Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Cyteir Therapeutics price performance over time
Historical closes compared with the close of $3.04 from 2022-07-01
1 week (2022-06-24) | 8.96% |
---|---|
1 month (2022-06-02) | 54.31% |
3 months (2022-04-01) | -26.39% |
6 months (2021-12-31) | -73.26% |
1 year (2021-07-02) | -84.32% |
---|---|
2 years (2020-06-28) | N/A |
3 years (2019-06-28) | N/A |
5 years (2017-06-28) | N/A |
Cyteir Therapeutics financials
Gross profit TTM | $-16,591,000 |
---|---|
Return on assets TTM | -22.4% |
Return on equity TTM | -38.06% |
Profit margin | 0% |
Book value | $4.95 |
Market capitalisation | $98.8 million |
TTM: trailing 12 months
Cyteir Therapeutics share dividends
We're not expecting Cyteir Therapeutics to pay a dividend over the next 12 months.
Have Cyteir Therapeutics's shares ever split?
Cyteir Therapeutics's shares were split on a 2:1 basis on 17 September 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cyteir Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cyteir Therapeutics shares which in turn could have impacted Cyteir Therapeutics's share price.
Cyteir Therapeutics overview
Cyteir Therapeutics, Inc. , a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts. .
Frequently asked questions
What percentage of Cyteir Therapeutics is owned by insiders or institutions?Currently 11.559% of Cyteir Therapeutics shares are held by insiders and 81.885% by institutions. How many people work for Cyteir Therapeutics?
Latest data suggests 40 work at Cyteir Therapeutics. When does the fiscal year end for Cyteir Therapeutics?
Cyteir Therapeutics's fiscal year ends in December. Where is Cyteir Therapeutics based?
Cyteir Therapeutics's address is: 128 Spring Street, Lexington, MA, United States, 02421 What is Cyteir Therapeutics's ISIN number?
Cyteir Therapeutics's international securities identification number is: US23284P1030
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert